当前位置: 首页 >> 检索结果
621. Association between depression and anxiety and inability to achieve remission in rheumatoid arthritis and psoriatic arthritis.
作者: Selinde V J Snoeck Henkemans.;Marijn Vis.;Gonul Hazal Koc.;Jolanda J Luime.;Marc R Kok.;Ilja Tchetverikov.;Sjoerd M van der Kooij.;Jessica Bijsterbosch.;Annette H M van der Helm-van Mil.;Pascal H P de Jong.
来源: Rheumatology (Oxford). 2025年64卷5期2411-2421页
To investigate the association between depression and anxiety and the inability to achieve remission in RA and PsA patients. In addition, the association between depressive and anxiety symptoms and disease activity components was explored.
622. MUC5B promoter variant and survival in rheumatoid arthritis-associated interstitial lung disease.
作者: Jacob Klein.;Austin M Wheeler.;Joshua F Baker.;Yangyuna Yang.;Punyasha Roul.;Halie Frideres.;Katherine D Wysham.;Gail S Kerr.;Andreas Reimold.;Dana P Ascherman.;Gary A Kunkel.;Grant W Cannon.;Paul A Monach.;Jill A Poole.;Geoffrey M Thiele.;Ted R Mikuls.;Bryant R England.
来源: Rheumatology (Oxford). 2025年64卷SI期SI47-SI54页
The objective of this study was to investigate the association between the MUC5B rs35705950 promoter variant and survival in RA-associated interstitial lung disease (RA-ILD).
623. Inclusion body myositis and immunosenescence: current evidence and future perspectives.
作者: Nur Azizah Allameen.;Sharfaraz Salam.;Venkat Reddy.;Pedro M Machado.
来源: Rheumatology (Oxford). 2025年64卷3期952-961页
IBM remains an enigmatic and complex muscle disorder where a deeper understanding of disease pathomechanisms and the identification of potential genetic contributors represent an unmet need. The absence of effective treatments has spurred endeavours to reassess the interplay between degeneration, including autophagy, mitochondrial dysfunction and proteasomal dysregulation, and autoimmunity. IBM is unique among the other idiopathic inflammatory myopathies owing to its molecular signature involving highly differentiated cytotoxic T cells that evade immune regulation. This has led to a resurgence of interest in the development of immunomodulatory therapy. This review discusses the potential role of cellular immunosenescence in sustaining inflammation and/or fibrotic remodelling observed in IBM and appraises the rationale for some potential therapeutic approaches to mitigate disease progression.
624. Classification of salivary gland biopsies in Sjögren's syndrome by a convolutional neural network using an auto-machine learning platform.
作者: Jorge Álvarez Troncoso.;Elena Ruiz-Bravo.;Clara Soto Abánades.;Alexandre Dumusc.;Álvaro López-Janeiro.;Thomas Hügle.
来源: BMC Rheumatol. 2024年8卷1期60页
The histopathological analysis of minor salivary gland biopsies, particularly through the quantification of the Focus Score (FS), is pivotal in the diagnostic workflow for Sjögren's Syndrome (SS). AI-based image recognition using deep learning models has demonstrated potential in enhancing diagnostic accuracy and efficiency in preclinical research.
625. Prevalence of co-existing autoimmune and autoinflammatory diseases in vitiligo: a survey-based study from Egypt.
The exact cause of vitiligo is still unknown. Genetic factors, self-destruction of melanocytes, the autoimmune process, and oxidative stress all can contribute to the pathogenesis of vitiligo.
626. Norwegian society of rheumatology recommendations on diagnosis and treatment of patients with Polymyalgia Rheumatica: a narrative review.
作者: Stig Tengesdal.;Andreas P Diamantopoulos.;Lene Kristin Brekke.;Emilio Besada.;Geirmund Myklebust.
来源: BMC Rheumatol. 2024年8卷1期58页
To provide evidence-based, up-to-date recommendations for physicians in primary and specialist healthcare setting in diagnosing and treating patients with polymyalgia rheumatica (PMR).
627. Temporal and regional variation in the use of biologic and targeted synthetic DMARDs for rheumatoid arthritis: a nationwide cohort study.
作者: Mark D Russell.;Zijing Yang.;Niamh Dooley.;Mark Gibson.;Benjamin Zuckerman.;Maryam A Adas.;Edward Alveyn.;Samir Patel.;Katie Bechman.;Elizabeth Price.;Sarah Gallagher.;Callum Coalwood.;Andrew P Cope.;Sam Norton.;James B Galloway.
来源: Rheumatology (Oxford). 2025年64卷5期2432-2441页
The objective of this study was to evaluate temporal and regional variation in biologic and targeted synthetic DMARD (b/tsDMARD) initiation for RA in England and Wales.
628. Headaches in SLE patients: a cross-sectional analysis of clinical, immunological, and Radiological Correlations.
Systemic Lupus Erythematosus (SLE) is a multifaceted autoimmune disorder characterized by diverse clinical manifestations, including a significant prevalence of headaches. This cross-sectional study aimed to thoroughly explore the relationship between SLE and headaches by analysing their prevalence, types, and associated clinical, immunological, and radiological factors.
629. What are the functional and clinical characteristics shared by fibromyalgia and low back pain? A scoping review.
作者: Bastien Couëpel.;Mathieu Tremblay.;Marjorie Bernier.;Jacques Abboud.;Martin Descarreaux.
来源: BMC Rheumatol. 2024年8卷1期56页
Fibromyalgia and chronic primary low back pain are two chronic pain conditions with a significant biopsychosocial burden. Recently, the International Association for the Study of Pain has grouped them under the term chronic primary pain. To further explore similarities and differences between these two conditions, the objective of this scoping review is to explore the pain-related, physiological and psychological outcomes in individuals with fibromyalgia and low back pain.
630. Contributors to organ damage in childhood lupus: corticosteroid use and disease activity.
作者: Maria Hanif.;Chandni Sarker.;Eslam Al-Abadi.;Kate Armon.;Kathryn Bailey.;Marek Bohm.;Mary Brennan.;Coziana Ciurtin.;Janet Gardner-Medwin.;Daniel P Hawley.;Alison Kinder.;Alice Leahy.;Gulshan Malik.;Zoe McLaren.;Elena Moraitis.;Ellen Mosley.;Athimalaipet V Ramanan.;Satyapal Rangaraj.;Annie Ratcliffe.;Philip Riley.;Heather Rostron.;Ethan Sen.;Michael W Beresford.;Eve M D Smith.
来源: Rheumatology (Oxford). 2025年64卷5期3028-3038页
Awareness of paediatric-specific predictors of damage in childhood lupus is needed to inform mitigation measures. The objective of this study was to ascertain how clinical and demographic variables correlate with damage accrual and identify predictors of damage.
631. Correction: Patient-reported outcome measures for systemic lupus erythematosus: an expert Delphi consensus to guide implementation in routine care.
作者: Isabel Castrejón.;Laura Cano.;María José Cuadrado.;Joaquín Borrás.;Maria Galindo.;Tarek C Salman-Monte.;Carlos Amorós.;Carmen San Román.;Isabel Cabezas.;Marta Comellas.;Alejandro Muñoz.
来源: BMC Rheumatol. 2024年8卷1期55页 632. Fatigue levels and associated factors in systemic sclerosis: a cross-sectional study of 2385 SPIN Cohort participants.
作者: Linda Kwakkenbos.;Brooke Levis.;Richard S Henry.;Gabrielle Virgili-Gervais.;Marie-Eve Carrier.;Susan J Bartlett.;Amy Gietzen.;Karen Gottesman.;Geneviève Guillot.;Amanda Lawrie-Jones.;Laura K Hummers.;Vanessa L Malcarne.;Maureen D Mayes.;Michelle Richard.;Robyn K Wojeck.;Maureen Worron-Sauvé.;Marie Hudson.;Luc Mouthon.;Andrea Benedetti.;Brett D Thombs.; .
来源: Rheumatology (Oxford). 2025年64卷5期2810-2820页
The objectives of this study were to compare fatigue in a large multinational SSc cohort with general population data and identify associated sociodemographic, lifestyle and SSc disease factors.
633. Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS.
作者: Laure Gossec.;Xenofon Baraliakos.;Daniel Aletaha.;Mohamed Sharaf.;Emmanouil Rampakakis.;Frédéric Lavie.;Clementina López-Medina.;Carlo Selmi.;Laura C Coates.
来源: Rheumatology (Oxford). 2025年64卷5期2565-2574页
Evaluate guselkumab efficacy, an anti-interleukin-23p19-subunit antibody, in patients with active psoriatic arthritis (PsA) and inadequate response to 1 or 2 tumour necrosis factor inhibitors (TNFi-IR), utilizing composite indices assessing disease activity across disease domains.
634. RNA sequencing uncovers key players of cartilage calcification: potential implications for osteoarthritis pathogenesis.
作者: Ilaria Bernabei.;Elodie Faure.;Julien Wegrzyn.;Nicolas Bertheaume.;Guillaume Falgayrac.;Thomas Hugle.;Sonia Nasi.;Nathalie Busso.
来源: Rheumatology (Oxford). 2025年64卷5期3151-3159页
OA is a joint disease linked with pathologic cartilage calcification, caused by the deposition of calcium-containing crystals by chondrocytes. Despite its clinical significance, the precise mechanisms driving calcification remain elusive. This study aimed to identify crucial players in cartilage calcification, offering insights for future targeted interventions against OA.
635. Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study.
作者: Mark D Russell.;Mark Gibson.;Benjamin Zuckerman.;Kanta Kumar.;Shirish Dubey.;Maryam A Adas.;Edward Alveyn.;Samir Patel.;Zijing Yang.;Katie Bechman.;Elizabeth Price.;Sarah Gallagher.;Andrew P Cope.;Sam Norton.;James B Galloway.
来源: Lancet Rheumatol. 2025年7卷1期e44-e54页
Quantifying health-care inequality is essential to addressing the imbalance in outcomes attributable to age, sex, race or ethnicity, and multimorbidity. In this study, we analysed differences in the initiation of biological or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis within the universal health-care system of England and Wales, UK.
636. Comment on: Fibroblast activation protein inhibitor-positron emission tomography in aortitis: fibroblast pathology in active inflammation and remission.
作者: Ertugrul Cagri Bolek.;Hazan Karadeniz.;Abdurrahman Tufan.
来源: Rheumatology (Oxford). 2025年64卷6期4087-4088页 637. ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository ("Registry").
作者: Irene Cecchi.;Massimo Radin.;Silvia Grazietta Foddai.;Alice Barinotti.;Danieli Andrade.;Maria G Tektonidou.;Vittorio Pengo.;Guillermo Ruiz-Irastorza.;H Michael Belmont.;Chary Lopez Pedrera.;Paul R Fortin.;Maria Gerosa.;Guilherme de Jesús.;Tatsuya Atsumi.;Lanlan Ji.;Maria Efthymiou.;D Ware Branch.;Cecilia Nalli.;Esther Rodriguez-Almaraz.;Michelle Petri.;Ricard Cervera.;Jason S Knight.;Bahar Artim-Esen.;Rohan Willis.;Maria Laura Bertolaccini.;Hannah Cohen.;Doruk Erkan.;Savino Sciascia.
来源: Rheumatology (Oxford). 2025年64卷5期2862-2867页
This study focused on the prevalence and impact of ANA in aPL-positive patients without concomitant systemic autoimmune rheumatic diseases (SARDs).
638. Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial.
作者: Arthur Kavanaugh.;Laura C Coates.;Philip J Mease.;Miroslawa Nowak.;Lauren Hippeli.;Thomas Lehman.;Subhashis Banerjee.;Joseph F Merola.
来源: Rheumatology (Oxford). 2025年64卷5期2557-2564页
Deucravacitinib is a novel, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor belonging to a distinct class of enzyme inhibitors. In a phase 2 trial in psoriatic arthritis (NCT03881059), deucravacitinib was significantly more efficacious than placebo across multiple endpoints, including achieving minimal disease activity (MDA). This post hoc analysis further evaluated the achievement of individual components of the MDA criteria with deucravacitinib treatment and the time course of responses in the phase 2 trial.
639. FAM13A polymorphism is associated with a usual interstitial pneumonia pattern in patients with systemic sclerosis-associated interstitial lung disease.
作者: Elana J Bernstein.;Francesco Boin.;Brett Elicker.;Yiming Luo.;Yawen Ren.;Meng Zhang.;John Varga.;Shervin Assassi.
来源: Rheumatology (Oxford). 2025年64卷SI期SI73-SI78页
The MUC5B promoter single nucleotide polymorphism (SNP) rs35705950 has been associated with idiopathic pulmonary fibrosis (IPF) and RA-related interstitial lung disease (ILD), but not with SSc-ILD. We hypothesized that the MUC5B promoter polymorphism or other IPF susceptibility loci are associated with an increased risk for the uncommon SSc-usual interstitial pneumonia (UIP) endophenotype, rather than SSc-ILD in general.
640. Correlations among quality of life, spinal mobility, and disease activity in early-treated axial spondyloarthritis: a single-center cross-sectional study.
作者: Tinh Khampaen.;Thanuchporn Kafaksom.;Nichapa Dechapaphapitak.;Nattakirana Tongdee.;Parawee Chevaisrakul.
来源: BMC Rheumatol. 2024年8卷1期54页
Axial spondyloarthritis (axSpA) significantly impacts patients' lives. The ASAS-OMERACT guideline was formulated for the multidimensional evaluation of axSpA patients, employing a specific set of tools. Given the pivotal role of patient perception, comprehensive correlation among these tools, especially concerning quality of life, may provide a clinically relevant perspective and enhance treatment efficacy in the early stages of the disease. This study aims to investigate the correlation among disease activity, functional ability, and quality of life in early-treated axSpA patients. In addition, the association between high disease activity and clinical characteristics was explored.
|